Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03182933 · ClinicalTrials.gov registry record · Phase 4
Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty
A Phase 4 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 4
- Development phase
- 64
- Enrollment target
NCT03182933: Clinical Trial Phase 4 study, sponsored by University of Wisconsin, Madison.
NCT03182933 is a Phase 4 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 64 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03182933, a Phase 4 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 64 participants
- Enrollment target
Study Summary
Study will evaluate the effect of liposomal bupivacaine versus standard bupivacaine on physical therapy measures and pain scores as well as opiate consumption.
Primary Outcome
Time to comfortably walk 10 meters as deemed safe by physical therapy
Interventions
- DRUG Peripheral Nerve Blockade
- BEHAVIORAL 10 meter walk test on post-operative day 1
- OTHER In person and over the phone questionnaire
- DEVICE Force transduction of quadriceps strength
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2017-05-30 |
| Est. Completion | 2018-07-16 |
| Phase | Phase 4 |
Why NCT03182933 stopped before completion
NCT03182933 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 4 interventions - of which Peripheral Nerve Blockade is the first listed.
NCT03182933 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03182933 about?
NCT03182933 is a clinical study titled "Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty". Study will evaluate the effect of liposomal bupivacaine versus standard bupivacaine on physical therapy measures and pain scores as well as opiate consumption.
What is the current status of trial NCT03182933?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 64 participants. The study started on 2017-05-30. Estimated completion is 2018-07-16.
What interventions are being tested in trial NCT03182933?
The interventions under investigation include: Peripheral Nerve Blockade (DRUG), 10 meter walk test on post-operative day 1 (BEHAVIORAL), In person and over the phone questionnaire (OTHER), Force transduction of quadriceps strength (DEVICE).
Who is sponsoring clinical trial NCT03182933?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03182933's enrollment target sits among peer trials
64 1098th of 2000 higher than 895 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI